We continue to monitor COVID-19, flu and other respiratory viruses in our communities. Read the most current information about prevention, testing and where to go if you're sick.

COVID-19 Information
Select the search type
  • Site
  • Web

Marrow Transplant Program Completes 5,000th Procedure

The bone marrow and stem cell transplant program at Siteman Cancer Center has achieved an important clinical landmark—5,000 transplants. Physicians performed the milestone transplant in July on a patient with multiple myeloma.

“Taking care of one transplant patient is a phenomenal amount of work,” says John DiPersio, MD, PhD, Siteman deputy director and chief of the Division of Oncology at Washington University School of Medicine. “It requires a critical mass of physicians, physician-scientists, nurses and nurse practitioners. To have achieved 5,000—it’s an enormous undertaking.”

The transplant program was established at Washington University and Barnes-Jewish Hospital in 1980. The first recorded transplant was performed in 1982 with marrow from a matched sibling pair. This year, the program expects to perform 400 transplants, including about 120 allogeneic transplants, making it one of the largest transplant centers in the country.

According to DiPersio, a transplant physician who led the program from 1994 to 2006, one of the program’s greatest assets is its faculty. “We have a strong mix of basic scientists, translational investigators and clinicians who are active in clinical research,” he says.

The transplant program is fully integrated with Siteman’s hematologic malignancies program. At any given time, the group offers more than 40 therapeutic clinical trials. “We put about 50 percent of our new patients on trials,” DiPersio says. “This includes institutional trials that are driven by institutional science.”

In recent years, Siteman physicians have conducted clinical studies that led to the approval of plerixafor as a mobilizing agent in patients with non-Hodgkin lymphoma and multiple myeloma, and decitabine as a first-line treatment for elderly patients with acute myelogenous leukemia (AML). They also were the first to use a novel suicide gene for gene therapy to control graft-versus-host disease.

In 2008, scientists affiliated with Siteman and Washington University’s Genome Institute became the first in the world to sequence the genome of a cancer patient, a woman with AML. This achievement has been followed by a series of studies that highlights the diagnostic and therapeutic potential of whole genome sequencing in hematologic malignancies.

Learn more about the 5,000th transplant and the history of Siteman’s bone marrow transplant program.

Find a doctor or make an appointment: 866.867.3627
General Information: 314.747.3000
One Barnes-Jewish Plaza
St. Louis, MO 63110
© Copyright 1997-2023, Barnes-Jewish Hospital. All Rights Reserved.